Home > Interventional Cardiology > BIO-RESORT Trial


von-Birgelen et al report the results of the BIO-RESORT trial. This was a 3 armed randomized clinical trial of thin strut biodegradable polymer EES, thin strut biodegradable polymer SES, thin strut durable polymer ZES. Both devices were within non-inferiority margin.



In patients with coronary artery disease, treated with durable polymer-coated drug-eluting stents, the
life-long presence of the polymer might delay arterial healing. Novel very thin strut biodegradable polymer stents, which
leave only a bare metal stent after polymer resorption, might improve long-term outcome. We investigated in allcomers
the safety and efficacy of three stents eluting either everolimus, sirolimus, or zotarolimus, often clinically used but
never compared, of which the biodegradable polymer everolimus-eluting stent was never before assessed in allcomers.


The large-scale, investigator-initiated, multicentre, assessor and patient blinded, three-arm, randomised,
BIO-RESORT non-inferiority trial was done at four clinical sites in the Netherlands. All-comer patients were aged
18 years or older, capable of providing informed consent, and required a percutaneous coronary intervention with
drug-eluting stent implantation according to clinical guidelines or the operators’ judgment. Exclusion criteria were:
participation in another randomised drug or device study before reaching the primary endpoint of that study;
planned surgery necessitating interruption of dual antiplatelet therapy within the first 6 months; known intolerance
to components of the investigational product or medication required; uncertainty about the adherence to follow-up
procedures or an assumed life expectancy of less than 1 year; or known pregnancy. Web-based computer-generated
allocation sequences randomly assigned patients (1:1:1) to treatment with very thin strut biodegradable polymer
everolimus-eluting or sirolimus-eluting stents (which diff er substantially in type, amount, distribution, and
resorption speed of their respective coating), or thin strut durable polymer zotarolimus-eluting stents. The primary
endpoint was a composite of safety (cardiac death or target vessel-related myocardial infarction) and efficacy (target
vessel revascularisation) at 12 months of follow up with a very thin strut biodegradable polymer of either
everolimus-eluting or sirolimus-eluting stents, compared with durable polymer zotarolimus-eluting stents,
analysed by intention to treat (non-inferiority margin 3·5%). This trial was registered with ClinicalTrials.gov,
number NCT01674803.


From Dec 21, 2012, to Aug 24, 2015, 3514 patients were enrolled and analysed, of whom 2449 (70%) had acute
coronary syndromes, which included 1073 (31%) ST-elevation myocardial infarctions. 12 month follow-up of
3490 (99%) patients (three lost to follow-up; 21 withdrawals) was available. The primary endpoint was met by 55 (5%)
of 1172 patients assigned to everolimus-eluting stents, 55 (5%) of 1169 assigned to sirolimus-eluting stents and 63 (5%)
of 1173 assigned to zotarolimus-eluting stents. Non-inferiority of the everolimus-eluting stents and sirolimus-eluting
stents compared with zotarolimus-eluting stents was confirmed (both –0·7% absolute risk difference, 95% CI
–2·4 to 1·1; upper limit of one sided 95% CI 0·8%, p non-inferiority<0·0001). Definite stent thrombosis (defined by the
Academic Research Consortium) occurred in four (0·3%) of 1172 patients who were allocated to everolimus-eluting
stents, four (0·3%) of 1169 patients who were allocated to sirolimus-eluting stents, and three (0·3%) of 1173 patients
who were allocated to zotarolimus-eluting stents (log-rank p=0·70 for both comparisons with zotarolimus-eluting


At 12 month follow-up, both very thin strut drug-eluting stents with dissimilar biodegradable polymer
coatings (eluting either everolimus or sirolimus) were non-inferior to the durable polymer stent (eluting zotarolimus)
in treating allcomers with a high proportion of patients with acute coronary syndromes. The absence of a loss of
1 year safety and efficacy with the use of these two biodegradable polymer-coated stents is a prerequisite before
assessing their potential longer-term benefits.


  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: